These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 7675867)
21. Kappa-opioid agonist U69593 potentiates locomotor sensitization to the D2/D3 agonist quinpirole: pre- and postsynaptic mechanisms. Perreault ML; Graham D; Bisnaire L; Simms J; Hayton S; Szechtman H Neuropsychopharmacology; 2006 Sep; 31(9):1967-81. PubMed ID: 16237381 [TBL] [Abstract][Full Text] [Related]
22. Modulation of the locomotor activating effects of the noncompetitive NMDA receptor antagonist MK801 by dopamine D2/3 receptor agonists in mice. Cook CD; Newman JL; Winfree JC; Beardsley PM Pharmacol Biochem Behav; 2004 Feb; 77(2):309-18. PubMed ID: 14751459 [TBL] [Abstract][Full Text] [Related]
23. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Svensson K; Carlsson A; Huff RM; Kling-Petersen T; Waters N Eur J Pharmacol; 1994 Oct; 263(3):235-43. PubMed ID: 7843260 [TBL] [Abstract][Full Text] [Related]
24. Modification of the behavioral effects of the selective dopamine D2 agonist (+)-4-propyl-9-hydroxynaphthoxazine by dopamine antagonists in monkeys. Rosenzweig-Lipson S; Bergman J J Pharmacol Exp Ther; 1993 Jun; 265(3):1039-46. PubMed ID: 8099614 [TBL] [Abstract][Full Text] [Related]
25. Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists. Khroyan TV; Barrett-Larimore RL; Rowlett JK; Spealman RD J Pharmacol Exp Ther; 2000 Aug; 294(2):680-7. PubMed ID: 10900248 [TBL] [Abstract][Full Text] [Related]
26. Morphine alters the locomotor responses to a D2/D3 dopamine receptor agonist differentially in adolescent and adult mice. Hofford RS; Wellman PJ; Eitan S J Psychopharmacol; 2012 Oct; 26(10):1355-65. PubMed ID: 22522973 [TBL] [Abstract][Full Text] [Related]
27. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184 [TBL] [Abstract][Full Text] [Related]
28. Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics. Ninan I; Kulkarni SK Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):603-8. PubMed ID: 10669905 [TBL] [Abstract][Full Text] [Related]
29. Reduced expression of haloperidol conditioned catalepsy in rats by the dopamine D3 receptor antagonists nafadotride and NGB 2904. Banasikowski TJ; Beninger RJ Eur Neuropsychopharmacol; 2012 Oct; 22(10):761-8. PubMed ID: 22410316 [TBL] [Abstract][Full Text] [Related]
30. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Brocco M; Dekeyne A; Papp M; Millan MJ Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388 [TBL] [Abstract][Full Text] [Related]
31. Effects of buspirone on dopamine dependent behaviours in rats. Dhavalshankh AG; Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Balsara JJ Indian J Physiol Pharmacol; 2007; 51(4):375-86. PubMed ID: 18476392 [TBL] [Abstract][Full Text] [Related]
32. Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol. Hashimoto T; Baba S; Ikeda H; Oda Y; Hashimoto K; Shimizu I Eur J Pharmacol; 2018 Jul; 830():26-32. PubMed ID: 29684390 [TBL] [Abstract][Full Text] [Related]
33. Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice. Boulay D; Depoortere R; Oblin A; Sanger DJ; Schoemaker H; Perrault G Eur J Pharmacol; 2000 Mar; 391(1-2):63-73. PubMed ID: 10720636 [TBL] [Abstract][Full Text] [Related]
34. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181 [TBL] [Abstract][Full Text] [Related]
35. A dose-response study of separate and combined effects of the serotonin agonist 8-OH-DPAT and the dopamine agonist quinpirole on locomotor sensitization, cross-sensitization, and conditioned activity. Johnson EF; Szechtman H Behav Pharmacol; 2016 Aug; 27(5):439-50. PubMed ID: 26871406 [TBL] [Abstract][Full Text] [Related]
36. D2 receptors inhibit the secretory process downstream from calcium influx in dopaminergic neurons: implication of K+ channels. Congar P; Bergevin A; Trudeau LE J Neurophysiol; 2002 Feb; 87(2):1046-56. PubMed ID: 11826068 [TBL] [Abstract][Full Text] [Related]
37. Differential effects of dopamine D2 agonist quinpirole upon the dorsal immobility response in rats. Meyer ME; Meyer ME; Potter TJ; Van Hartesveldt C Pharmacol Biochem Behav; 1992 Jun; 42(2):257-9. PubMed ID: 1352900 [TBL] [Abstract][Full Text] [Related]
38. Postnatal lead exposure induces supersensitivity to the stimulus properties of a D2-D3 agonist. Cory-Slechta DA; Pokora MJ; Widzowski DV Brain Res; 1992 Dec; 598(1-2):162-72. PubMed ID: 1362517 [TBL] [Abstract][Full Text] [Related]
39. D2-agonist quinpirole induces perseveration of routes and hyperactivity but no perseveration of movements. Eilam D; Golani I; Szechtman H Brain Res; 1989 Jun; 490(2):255-67. PubMed ID: 2527582 [TBL] [Abstract][Full Text] [Related]
40. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Maj J; Rogóz Z; Skuza G; Kołodziejczyk K Eur J Pharmacol; 1997 Apr; 324(1):31-7. PubMed ID: 9137910 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]